Project Grant R44DK111304

This Project Grant award of $929,940 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop a first-in-class dual agonist biologic for safely treating Type I and Type II diabetics experiencing impaired awareness of hypoglycemia (IAH). The award, effective September 1, 2024 through August 31, 2026, will support manufacturing, formulation, efficacy validation,...

This Project Grant award, valued at $195,625.00 and funded by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research), will support preclinical studies to evaluate the long-term efficacy of AAV9-based gene therapy for classic galactosemia (CG) in a GALT-null rat model. The goal is to test whether a single intravenous dose of scAAV9-hGALT can prevent representative long-term complications associated with CG,...

This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $324,984 to Syntis Bio Inc. to develop an oral therapeutic platform for treating homocystinuria, a rare metabolic disorder. Specifically, the project aims to optimize a formulation combining a methionine-gamma-lyase enzyme with a gastrointestinal synthetic epithelial lining to...

This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to evaluate the real-world effectiveness and utilization of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the treatment of type 2 diabetes in adolescents and young adults (AYAs). The $261,596 award to The Children's Hospital of Philadelphia Research Institute will fund a...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports the development of a novel therapeutic antibody for the treatment of acromegaly. Acromegaly is a rare endocrine disorder that leads to excess growth hormone production and serious health complications. The $1,035,589 award, spanning September 2024 to July 2026, aims to prepare the...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to demonstrate the efficacy of using hydrodynamic gene delivery to provide lifelong correction of Hereditary Tyrosinemia Type 1 (HT1) and other monogenic liver diseases. The $881,961 award to Hydrogene Therapeutics Inc. will fund a Fast-Track project to optimize a non-viral vector system...

This $335,410 federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports the development of a needle-free microneedle array patch (MAP) for delivering a GLP-1 receptor agonist to treat type 2 diabetes. The grant recipient, Vaxess Technologies, Inc., is a biotechnology company specializing in innovative MAP technologies for drug and vaccine...

The National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases awarded $3.6 million under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Anagram Therapeutics Inc. to develop a novel pancreatic enzyme replacement therapy. Specifically, Anagram will engineer lipase enzymes for improved stability against low pH and proteolytic degradation. This will allow for effective digestion of fats in both the stomach and small...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports the development of a long-acting parathyroid hormone (PTH) derivative, EXT608, for the treatment of hypoparathyroidism. The $999,615 award to Extend Biosciences Inc., a woman-owned small business, will fund a Phase 2 clinical trial to evaluate the safety, tolerability, and efficacy of...

This Project Grant award of $1,107,090, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research, supports research at The General Hospital Corporation (doing business as Massachusetts General Hospital) to investigate the regulation of G protein alpha subunit (Gsα) expression and its role in hormone signaling. The research aims to elucidate the mechanisms by which GNAS gene...